Avanish Vellanki, Rain Oncology CEO
December 14, 2023 07:08 AM ESTUpdated 07:27 AM
Deals

Pathos AI makes suc­cess­ful takeover bid for Rain On­col­o­gy

Katherine Lewin

News Reporter

Pathos AI is ac­quir­ing Rain On­col­o­gy for $1.16 in cash per share plus a non-trad­able con­tin­gent val­ue right for po­ten­tial cash …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump picks vac­cine skep­tic Kennedy to lead HHS, in what would be an up­heaval of US health pol­i­cy

Eu­ro­pean drug reg­u­la­tor re­vers­es opin­ion on Ei­sai and Bio­gen's Alzheimer's drug

BeiGene will re­brand to BeOne Med­i­cines, drop­ping name's link to Chi­na roots

Gilead will close Philadel­phia, Seat­tle of­fices as part of job re­duc­tions

Mer­ck buys in­to PD-1/VEGF space as Sum­mit comes for Keytru­da

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times